Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: β-catenin drives resistance to PI3K and AKT inhibitors and promotes colon cancer metastasis by disrupting FOXO3a function

  • By

  • Stephan P. Tenbaum

  • Paloma Ordóñez-Morán

  • Isabel Puig

  • Irene Chicote

  • Oriol Arqués

  • Stefania Landolfi

  • Yolanda Fernández

  • José Raúl Herance

  • Juan D. Gispert

  • Leire Mendizabal

  • Susana Aguilar

  • Santiago Ramón y. Cajal

  • Simó Schwartz

  • Ana Vivancos

  • Eloy Espín

  • Santiago Rojas

  • José Baselga

  • Josep Tabernero

  • Alberto Muñoz

  • Héctor G. Palmer

  • October 22, 2026

Share

Clinical Scorecard: Author Correction: β-catenin drives resistance to PI3K and AKT inhibitors and promotes colon cancer metastasis by disrupting FOXO3a function

At a Glance

CategoryDetail
ConditionNot specified in the correction notice.
Key MechanismsThe correction notice reports an image correction and provides no mechanistic details.
Target PopulationNot specified in the correction notice.
Care SettingNot specified in the correction notice.

Key Highlights

  • The correction concerns a Nature Medicine report with DOI 10.1038/nm.2772, published online on 20 May 2012.
  • The “T49, Xenograft” panel in Fig. 6b originally contained an image duplicated from Fig. 1b.
  • The corrected Fig. 6b replaces that panel with a different representative confocal image corresponding to the staining described.
  • The notice amends the identified error in the originally published article.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          No patient population or prescribing data are provided in the correction notice.

          No treatment or prescribing recommendations are provided.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

            • by Stephan P. Tenbaum, Paloma Ordóñez-Morán, Isabel Puig, Irene Chicote, Oriol Arqués, Stefania Landolfi, Yolanda Fernández, José Raúl Herance, Juan D. Gispert, Leire Mendizabal, Susana Aguilar, Santiago Ramón y. Cajal, Simó Schwartz, Ana Vivancos, Eloy Espín, Santiago Rojas, José Baselga, Josep Tabernero, Alberto Muñoz, Héctor G. Palmer

            • October 22, 2026

            Related Content

            EQUIPOISE: EQUivalence In Prostate cancer treatment: surgery Or radiotherapy? An Intention-to-treat Survival analysis from real-world Evidence

            Personalized Breast Cancer Screening: Moving Beyond Age-Based Algorithms

            Breast cancer screening has traditionally been organized around two principal variables: when mammography should begin and how frequently it should be performed.

            • by

            • October 16, 2026

            • 7 min
            Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors: A Secondary